Rheumatology

Your Article Summary

See Latest Articles

Adalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy
Core Evidence, 08/17/09

Hennigan S et al. – There is clear evidence that adalimumab, administered 40 mg subcutaneously every 2 weeks, substantially improves the signs and symptoms of NSAID–refractory, active AS when compared with placebo treatment. There is ample evidence that adalimumab causes significant improvements in physical health status and overall AS–specific, health–related quality of life and physical functioning, which consequently leads to better work productivity. There is substantial evidence that adalimumab improves spinal and sacroiliac joint inflammation in AS patients. Initial results from clinical trials suggest that there is no increased risk of serious infections or malignancies in adalimumab–treated patients with AS. The most common adverse events were injection–site reactions. Limited economic evidence suggests that adalimumab 40 mg may be cost effective when used according to current valid treatment guidelines.

Related Articles

See all related articles

Evaluation of inflammation and oxidative stress in ankylosing spondylitis: a role for macrophage migration inhibitory factor
Modern Rheumatology, 10/05/09    Relevance Score: 69%

Erythrocyte sedimentation rate, CRP level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis
Arthritis Care and Research, 11/02/09    Relevance Score: 68%

Uncommon case of ankylosing spondylitis associated with spontaneous occurring hypoparathyroidism
Rheumatology International, 11/11/09    Relevance Score: 67%

Concomitant cervical and thoracic spinal fractures in ankylosing spondylitis: A case report and review of literature
Injury Extra, 11/05/09    Relevance Score: 67%

A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis
Rheumatology International, 10/27/09    Relevance Score: 67%

Today in Clinical Pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts
Rheumatology, 12/11/09

Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: Systematic review and meta-analysis
Osteoporosis International, 12/10/09

The efficacy of calcitriol therapy in the management of bone loss and fractures: A qualitative review
Osteoporosis International, 12/10/09

 See all of Clinical Pharmacology

Today in Spondylarthropathies...keeping you current

Receive free subspecialty "5-minute updates" via email

A survey of European and Canadian rheumatologists regarding the treatment of patients with ankylosing spondylitis and extra-articular manifestations
Clinical Rheumatology, 12/11/09

Positron emission tomography/computed tomography: A clinical tool for evaluation of enthesitis in patients with spondyloarthritides
Rheumatology, 12/11/09

An epidemiological survey of low back pain and axial spondyloarthritis in a Chinese Han population
Scandinavian Journal of Rheumatology , 11/24/09

 See all of Spondylarthropathies